胃肠胰神经内分泌肿瘤诊疗进展  

Progress in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasm

作　　者：蔡文 倪寇 葛维挺[2] 张佳炜[2] 胡涵光[1,2] Cai Wen;Ni Kou;Ge Weiting;Zhang Jiawei;Hu Hanguang(Department of Medical Oncology,the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China;Cancer Institute(Key Laboratory of Cancer Prevention and Intervention,China National Ministry of Education),the Second Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310009,China)

机构地区：[1]浙江大学医学院附属第二医院肿瘤内科,浙江杭州310009 [2]浙江大学医学院附属第二医院肿瘤研究所(恶性肿瘤预警与干预教育部重点实验室),浙江杭州310009

出　　处：《实用肿瘤杂志》2023年第3期222-228,共7页Journal of Practical Oncology

基　　金：浙江省“尖兵”“领雁”研发攻关计划(2022C03002);浙江省自然科学基金(LY22H160024);白求恩·肿瘤基础研究计划项目[(2021)BCF-NH-ZL-202206-006]。

摘　　要：神经内分泌肿瘤(neuroendocrine neoplasm,NEN)的发病率和患病率近年来迅速增长,其中以原发于胃肠道和胰腺的NEN最常见。2022年,美国国家综合癌症网络(National Comprehensive Cancer Network,NCCN)NEN指南及中国胃肠胰NEN专家共识进行了更新。本文主要参照比对2022年NCCN指南及2022版中国胃肠胰NEN专家共识对NEN的诊疗新进展进行评述。The incidence and prevalence of neuroendocrine neoplasm(NEN)has increased rapidly in recent years,among which NENs originating from gastrointestinal tract and pancreas are the most common.In 2022,the National Comprehensive Cancer Network(NCCN)NEN guidelines and the Chinese expert consensus on gastroenteropancreatic NEN were updated.This article mainly reviews the new de-velopments in the diagnosis and treatment of NEN based on a comparison of the 2022 NCCN guidelines and the 2022 Chinese expert con-sensus on gastroenteropancreatic NEN.

关 键 词：神经内分泌肿瘤 胃肠胰肿瘤 诊断 治疗 

分 类 号：R735[医药卫生—肿瘤]